Last reviewed · How we verify

3% diclofenac in 2.5% hyaluronic acid gel

University Hospital Regensburg · FDA-approved active Small molecule Quality 0/100

3% diclofenac in 2.5% hyaluronic acid gel is a Small molecule drug developed by University Hospital Regensburg. It is currently FDA-approved. Also known as: Solaraze Gel.

At a glance

Generic name3% diclofenac in 2.5% hyaluronic acid gel
Also known asSolaraze Gel
SponsorUniversity Hospital Regensburg
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about 3% diclofenac in 2.5% hyaluronic acid gel

What is 3% diclofenac in 2.5% hyaluronic acid gel?

3% diclofenac in 2.5% hyaluronic acid gel is a Small molecule drug developed by University Hospital Regensburg.

Who makes 3% diclofenac in 2.5% hyaluronic acid gel?

3% diclofenac in 2.5% hyaluronic acid gel is developed and marketed by University Hospital Regensburg (see full University Hospital Regensburg pipeline at /company/university-hospital-regensburg).

Is 3% diclofenac in 2.5% hyaluronic acid gel also known as anything else?

3% diclofenac in 2.5% hyaluronic acid gel is also known as Solaraze Gel.

What development phase is 3% diclofenac in 2.5% hyaluronic acid gel in?

3% diclofenac in 2.5% hyaluronic acid gel is FDA-approved (marketed).

Related